Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Oncology Research Network

Neither a doctor nor a teaching hospital

Research payments

$184,470

38 payments

Through program year 2025, Clinical Oncology Research Network is reported as receiving $184,470 in research payments, across 38 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $4,766 1
2021 Research $275 1
2020 Research $29,151 10
2019 Research $150,277 26

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $57,233 18 payments
  2. Amgen Inc. $54,725 7 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $37,725 8 payments
  4. Helsinn Healthcare SA $29,249 4 payments
  5. Eisai Inc. $5,538 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab Anti-PD-1 Antibody and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer $50,152 16 payments
  2. Prospective Observational Study of Onpro vs SOC $34,295 2 payments
  3. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer NSCLC $25,793 3 payments
  4. Ph III Copanlisib+Rituximab in relapsed iNHL $20,300 2 payments
  5. Phase III RB/RCHOP +/- copanlisib in iNHL $17,425 6 payments
  6. LCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 1 $13,250 1 payment
  7. A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-Pd-1 Antibody) and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer $7,082 2 payments
  8. A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma $5,538 1 payment
  9. Prospective Observational Study of Onpro vs SOC. $4,980 3 payments
  10. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) $3,456 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record